Dual-Mechanism Drop Wins FDA Approval - Summary - MDSpire

Dual-Mechanism Drop Wins FDA Approval

FDA approves Tenpoint Therapeutics’ YUVEZZI eye drop for presbyopia

  • February 2, 2026

  • 2 min

Share

Objective:

To report the FDA approval of YUVEZZI™, a dual-agent eye drop for treating presbyopia in adults.

Key Findings:
  • YUVEZZI demonstrated superiority over its individual components in BRIO I.
  • In BRIO II, it achieved significant improvements in near visual acuity for up to eight hours.
  • Safety study included over 72,000 treatment days with no serious adverse events reported.
Interpretation:

The approval of YUVEZZI represents a significant advancement in non-invasive options for managing presbyopia, addressing patient needs for convenience and flexibility.

Limitations:
  • Long-term effects beyond the study duration are not yet known.
  • The trials primarily focused on short-term efficacy and safety.
Conclusion:

YUVEZZI's dual-mechanism approach and once-daily dosing may provide a valuable alternative for patients seeking pharmacologic correction of near vision.

Original Source(s)

Dual-Mechanism Drop Wins FDA Approval

  • February 2, 2026

Related Content

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.

  • July 8, 2025

  • 2 min
Profitable Presbyopia

Presbyopia is no longer a condition we simply accommodate; it has become a platform for a longitudinal relationship that can span decades.

The Growth Potential of Refractive Surgery for Myopia

Capitalizing on the growth potential of refractive surgery hinges on embracing an array of procedures, challenging conventional mindsets and prioritizing patient-centered care.